• Private placement of approximately 17.2 million new CHESS Depositary Interests
• Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million)
• Proceeds to be used for working capital and support continued growth of therapeutic acute wound portfolio

AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, announced the successful completion of a private placement to institutional and professional investors in Australia. The company issued approximately 17.2 million new CHESS Depositary Interests (CDIs) at an offer price of A$1.32 per CDI, raising an approximate gross amount of US$15 million (approximately A$23 million). The offer price represents an 11% discount to the last closing price of A$1.48 per CDI on the ASX. Proceeds from the placement will be used for working capital requirements and will provide additional strategic flexibility to support the continued growth of the company's therapeutic acute wound portfolio. This is expected to cover operations until free cash flow begins in 2026. Jim Corbett, Chief Executive Officer of AVITA Medical, stated that the strong support received in this placement reflects growing confidence in the company's strategy and the transformative potential of its therapeutic acute wound care portfolio. The new CDIs are expected to be settled on August 19, 2025, and to commence trading on the ASX shortly thereafter on August 20, 2025. The new CDIs will rank equally with the company's existing CDIs on issue.